Improvement of BMD after Switching from Lopinavir/R Plus Two Nucleos(T)ide Reverse Transcriptase Inhibitors to Lopinavir/R Plus Lamivudine: OLE-LIP Substudy

References

• McComsey GA, Tebas P, Shane E, et al. Bone disease in HIV infection: A practical review and recommendations for HIV care providers. Clin Infect Dis. 2010;51:937–946.10.1086/652982
   PubMed Web of Science ®Google Scholar
• Young B, Dao CN, Buchacz K, et al. Increased rates of bone fracture among HIV-infected persons in the HIV outpatient study (HOPS) compared with the US general population, 2000–2006. Clin Infect Dis. 2011;52:1061–1068.10.1093/cid/ciq242
   PubMed Web of Science ®Google Scholar
• Prieto-Alhambra D, Güerri-Fernández R, De Vries F, et al. HIV infection and its association with an excess risk of clinical fractures. J Acquir Immune Defic Syndr. 2014;66:90–95.10.1097/QAI.0000000000000112
   PubMed Web of Science ®Google Scholar
• Hileman CO, Labbato DE, Storer NJ, et al. Is bone loss linked to chronic inflammation in antiretroviral-naive HIV-infected adults? A 48-week matched cohort study. AIDS. 2014;28:1759–1767.10.1097/QAD.0000000000000320
   PubMed Web of Science ®Google Scholar
• Titanji K, Vunnava A, Sheth AN, et al. Dysregulated B cell expression of RANKL and OPG correlates with loss of bone mineral density in HIV infection. PLoS Pathog. 2014;10:e1004497.10.1371/journal.ppat.1004497
   PubMed Web of Science ®Google Scholar
• Gazzola L, Bellistri GM, Tincati C, et al. Association between peripheral T-Lymphocyte activation and impaired bone mineral density in HIV-infected patients. J Transl Med. 2013;11:51.10.1186/1479-5876-11-51
   PubMed Web of Science ®Google Scholar
• Grund B, Peng G, Gibert CL, et al. Continuous antiretroviral therapy decreases bone mineral density. AIDS. 2009;23:1519–1529.10.1097/QAD.0b013e32832c1792
   PubMed Web of Science ®Google Scholar
• Brown TT, McComsey GA, King MS, et al. Loss of bone mineral density after antiretroviral therapy initiation, independent of antiretroviral regimen. J Acquir Immune Defic Syndr. 2009;51:554–561.10.1097/QAI.0b013e3181adce44
   PubMed Web of Science ®Google Scholar
• Duvivier C, Kolta S, Assoumou L, et al. Greater decrease in bone mineral density with protease inhibitor regimens compared with nonnucleoside reverse transcriptase inhibitor regimens in HIV-1 infected naive patients. AIDS. 2009;27:817–824.10.1097/QAD.0b013e328328f789
   Web of Science ®Google Scholar
• McComsey GA, Kitch D, Daar ES, et al. Bone mineral density and fractures in antiretroviral-naive persons randomized to receive abacavir-lamivudine or tenofovir disoproxil fumarate-emtricitabine along with efavirenz or atazanavir-ritonavir: AIDS clinical trials group A5224s, a substudy of ACTG A5202. J Infect Dis. 2011;203:1791–1801.10.1093/infdis/jir188
   PubMed Web of Science ®Google Scholar
• Stellbrink HJ, Orkin C, Arribas JR, et al. Comparison of changes in bone density and turnover with abacavir‐lamivudine versus tenofovir‐emtricitabine in HIV‐infected adults: 48‐week results from the ASSERT study. Clin Infect Dis. 2010;51:963–972.10.1086/652982
   PubMed Web of Science ®Google Scholar
• Moyle GJ, Stellbrink HJ, Compston J, et al. 96-week results of abacavir/lamivudine versus tenofovir/emtricitabine, plus efavirenz, in antiretroviral-naive, HIV-1-infected adults: ASSERT study. Antiviral Ther. 2013;18:905–913.10.3851/IMP2667
   PubMed Web of Science ®Google Scholar
• Grant PM, Kitch D, McComsey GA, et al. Low baseline CD4 + count is associated with greater bone mineral density loss after antiretroviral therapy initiation. Clin Infect Dis. 2013;57:1483–1488.10.1093/cid/cit538
   PubMed Web of Science ®Google Scholar
• Negredo E, Domingo P, Ferrer E, et al. Peak bone mass in young HIV-infected patients compared with healthy controls. J Acquir Immune Defic Syndr. 2014;65:207–212.10.1097/01.qai.0000435598.20104.d6
   PubMed Web of Science ®Google Scholar
• Huang JS, Hughes MD, Riddler SA, et al. Bone mineral density effects of randomized regimen and nucleoside reverse transcriptase inhibitor selection from ACTG A5142. HIV Clin Trials. 2013;14:224–234.10.1310/hct1405-224
   PubMed Web of Science ®Google Scholar
• Looker AC, Wahner HW, Dunn WL, et al. Updated data on proximal femur bone mineral levels of US adults. Osteoporos Int. 1998;8:468–490.10.1007/s001980050093
   PubMed Web of Science ®Google Scholar
• Moyle GJ, Hardy H, Farajallah A, et al. Changes in bone mineral density after 96 weeks of treatment with atazanavir/ritonavir or lopinavir/ritonavir plus tenofovir DF/emtricitabine in treatment-naive patients with HIV-1 infection. J Acquir Immune Defic Syndr. 2015;68:40–45.10.1097/QAI.0000000000000383
   PubMed Web of Science ®Google Scholar
• Martinez E, Gonzalez-Cordon A, Ferrer E, et al. Differential body composition effects of protease inhibitors recommended for initial treatment of HIV infection: A randomized clinical trial. Clin Infect Dis. 2015;60:811–820.10.1093/cid/ciu898
   PubMed Web of Science ®Google Scholar
• Lake JE, Wohl D, Scherzer R, et al. Regional fat deposition and cardiovascular risk in HIV infection: The FRAM study. AIDS Care. 2011;23:929–938.10.1080/09540121.2010.543885
   PubMed Web of Science ®Google Scholar
• Curran A, Martinez E, Saumoy M, et al. Body composition changes after switching from protease inhibitors to raltegravir. AIDS. 2012;26:475–481.10.1097/QAD.0b013e32834f3507
   PubMed Web of Science ®Google Scholar
• Arribas JR, Girard PM, Landman R, et al. Dual treatment with lopinavir-ritonavir plus lamivudine versus triple treatment with lopinavir-ritonavir plus lamivudine or emtricitabine and a second nucleos(t)ide reverse transcriptase inhibitor for maintenance of HIV-1 viral suppression (OLE): A randomised, open-label, non-inferiority trial. Lancet Infect Dis. 2015;15:785–792.
   PubMed Web of Science ®Google Scholar
• Bernardino JI, Mocroft A, Mallon PW, et al. Bone mineral density and inflammatory and bone biomarkers after darunavir-ritonavir combined with either raltegravir or tenofovir-emtricitabine in antiretroviral-naive adults with HIV-1: A substudy of the NEAT001/ANRS143 randomised trial. Lancet HIV. 2015;2:e464–e473.10.1016/S2352-3018(15)00181-2
   PubMed Web of Science ®Google Scholar
• Bedimo RJ, Drechsler H, Jain M, et al. The RADAR study: Week 48 safety and efficacy of raltegravir combined with boosted darunavir compared to tenofovir/emtricitabine combined with boosted darunavir in antiretroviral-naive patients. impact on bone health. PLoS One. 2014;9:e106221.10.1371/journal.pone.0106221
   PubMed Web of Science ®Google Scholar
• Reynes J, Trinh R, Pulido F, et al. Lopinavir/ritonavir combined with raltegravir or tenofovir/emtricitabine in antiretroviral-naive subjects: 96-week results of the PROGRESS study. AIDS Res Hum Retroviruses. 2013;29:256–265.
   PubMed Web of Science ®Google Scholar
• Martin A, Moore C, Mallon PW, et al. Bone mineral density in HIV participants randomized to raltegravir and lopinavir/ritonavir compared with standard second line therapy. AIDS. 2013;27:2403–2411.10.1097/01.aids.0000432534.47217.b4
   PubMed Web of Science ®Google Scholar
• Martin A, Bloch M, Amin J, et al. Simplification of antiretroviral therapy with tenofovir‐emtricitabine or abacavir‐lamivudine: A randomized, 96‐week trial. Clin Infect Dis. 2009;49:1591–1601.10.1086/599193
   PubMed Web of Science ®Google Scholar
• Rasmussen TA, Jensen D, Tolstrup M, et al. Comparison of bone and renal effects in hiv-infected adults switching to abacavir or tenofovir based therapy in a randomized trial. PLoS ONE. 2012;7:e32445.10.1371/journal.pone.0032445
   PubMed Web of Science ®Google Scholar
• Hamzah L, Tiraboschi JM, Iveson H, et al. Effects on vitamin D, bone and the kidney of switching from fixed-dose tenofovir disoproxil fumarate/emtricitabine/efavirenz to darunavir/ritonavir monotherapy: A randomized, controlled trial (MIDAS). [Epub ahead of print Oct 13, 2015]. Antivir Ther. PMID: 26460504.
   Web of Science ®Google Scholar
• Labarga P, Barreiro P, Martin-Carbonero L, et al. Kidney tubular abnormalities in the absence of impaired glomerular function in HIV patients treated with tenofovir. AIDS. 2009;23:689–696.10.1097/QAD.0b013e3283262a64
   PubMed Web of Science ®Google Scholar
• Menzaghi BQT, Bonfanti P, Molteni C, et al. Bone metabolism and tenofovir: Evidence of direct effect on calcium-sensing receptor. In: 22nd Conference on Retroviruses and Opportunistic Infections (CROI); 2015, February 23–26; Seattle P-765.
   Google Scholar
• Cotter AG, Vrouenraets SM, Brady JJ, et al. Impact of switching from zidovudine to tenofovir disoproxil fumarate on bone mineral density and markers of bone metabolism in virologically suppressed HIV-1 infected patients; a substudy of the PREPARE study. J Clin Endocrinol Metab. 2013;98:1659–1666.10.1210/jc.2012-3686
   PubMed Web of Science ®Google Scholar
• Sax PE, Wohl D, Yin MT, et al. Tenofovir alafenamide versus tenofovir disoproxil fumarate, coformulated with elvitegravir, cobicistat, and emtricitabine, for initial treatment of HIV-1 infection: Two randomised, double-blind, phase 3, non-inferiority trials. Lancet. 2015;385:2606–2615.10.1016/S0140-6736(15)60616-X
   PubMed Web of Science ®Google Scholar
• Mills A, Arribas JR, Andrade-Villanueva J, et al. Switching from tenofovir disoproxil fumarate to tenofovir alafenamide in antiretroviral regimens for virologically suppressed adults with HIV-1 infection: A randomised, active-controlled, multicentre, open-label, phase 3, non-inferiority study. Lancet Infect Dis. 2016;16:43–52.10.1016/S1473-3099(15)00348-5
   PubMed Web of Science ®Google Scholar
• Grant PM, Kitch D, McComsey GA, et al. Differential skeletal impact of tenofovir disoproxil fumarate in young versus old HIV-infected adults. HIV Clin Trials. 2015;16:66–71.10.1179/1528433614Z.0000000010
   PubMed Web of Science ®Google Scholar
• Kinai E, Nishijima T, Mizushima D, et al. Long-term use of protease inhibitors is associated with bone mineral density loss. AIDS Res Hum Retroviruses. 2014;30:553–559.10.1089/aid.2013.0252
   PubMed Web of Science ®Google Scholar
• Bonjoch A, Figueras M, Estany C, et al. High prevalence of and progression to low bone mineral density in HIV-infected patients: A longitudinal cohort study. AIDS. 2010;24:2827–2833.10.1097/QAD.0b013e328340a28d
   PubMed Web of Science ®Google Scholar
• Hernandez-Vallejo SJ, Beaupere C, Larghero J, et al. HIV protease inhibitors induce senescence and alter osteoblastic potential of human bone marrow mesenchymal stem cells: Beneficial effect of pravastatin. Aging Cell. 2013;12:955–965.10.1111/acel.2013.12.issue-6
   PubMed Web of Science ®Google Scholar
• Brown TT, Hoy J, Borderi M, et al. Recommendations for evaluation and management of bone disease in HIV. Clin Infect Dis. 2015;60:1242–1251.10.1093/cid/civ010
   PubMed Web of Science ®Google Scholar
• Negredo E, Diez-Perez A, Bonjoch A, et al. Switching from tenofovir to abacavir in HIV-1-infected patients with low bone mineral density: Changes in bone turnover markers and circulating sclerostin levels. J antimicrob chemother. 2015;70:2104–2107.
   PubMed Web of Science ®Google Scholar
• Bloch M, Tong WW, Hoy J, et al. Switch from tenofovir to raltegravir increases low bone mineral density and decreases markers of bone turnover over 48 weeks. HIV Med. 2014;15:373–380.10.1111/hiv.2014.15.issue-6
   PubMed Web of Science ®Google Scholar